NewsBenzingaReported Earlier, HUTCHMED Announces AstraZeneca Submitted US NDA For ORPATHYS Plus TAGRISSO In MET-Driven EGFR-Mutated NSCLC, Supported By Phase III SAFFRON Trial Reported Earlier, HUTCHMED Announces AstraZeneca Submitted US NDA For ORPATHYS Plus TAGRISSO In MET-Driven EGFR-Mutated NSCLC, Supported By Phase III SAFFRON Trial Benzinga 2026.09.29 08:29 (GMT+0) Open on Benzinga Other news Ted Cruz Warns China Could Win in High-Stakes AI Race — 'Single Most Important Economic Question Facing America Today' Roth Capital Initiates Coverage On Nautilus Biotechnology with Buy Rating, Announces Price Target of $3.5 Stifel Upgrades Staar Surgical to Buy, Raises Price Target to $31 Stock Market Today: Dow Jones, S&P 500 Futures Slip, Nasdaq 100 Gains as Trump Dismisses Iran Sanction Relief as 'Hoax' — NVDA, AAR, MTN in Focus OpenAI to launch round-the-clock AI agents on Developer Day Baird Downgrades Ryder System to Neutral, Lowers Price Target to $245
Ted Cruz Warns China Could Win in High-Stakes AI Race — 'Single Most Important Economic Question Facing America Today'
Roth Capital Initiates Coverage On Nautilus Biotechnology with Buy Rating, Announces Price Target of $3.5
Stock Market Today: Dow Jones, S&P 500 Futures Slip, Nasdaq 100 Gains as Trump Dismisses Iran Sanction Relief as 'Hoax' — NVDA, AAR, MTN in Focus
